IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation

Publication date: Available online 14 July 2019Source: Pharmacological ResearchAuthor(s): Federica Raucci, Asif J. Iqbal, Anella Saviano, Paola Minosi, Marialuisa Piccolo, Carlo Irace, Francesco Caso, Raffaele Scarpa, Stefano Pieretti, Nicola Mascolo, Francesco MaioneAbstractGout is a paradigm of acute, self-limiting inflammation caused by the deposition of monosodium urate (MSU) crystals within intra-and/or peri-articular areas, which leads to excruciating pain, joint swelling and stiffness. The infiltration of leukocytes drives the inflammatory response and remains an attractive target for therapeutic intervention. In this context, emerging evidence support the view that systemic differentiation of Th17 cells and their in-situ infiltration as one of the potential mechanisms by which these cells, and their main product IL-17, causes damage to the target tissues. To test if IL-17 was having a detrimental role in gouty onset and progression we targeted this cytokine, using a neutralizing antibody strategy, in an experimental model of gout.Joint inflammation was induced in CD-1 mice by the intra-articular (i.a.) administration of MSU crystals (200 μg/20 µl). Animals from IL-17Ab-treated groups received 1, 3 and 10 µg (i.a.) in 20 µl of neutralizing antibody 30 minutes after MSU crystals administration. Thereafter, joints were scored macroscopically, and knee joint oedema determined with a caliper. Histological analyses, myeloperoxidase assay and western blots anal...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research